HGF and cancer: Therefore, specific binding of rilotumumab to HGF neutralizes the interaction between HGF and c-MET and inhibits c-MET phosphorylation and downstream signaling, resulting in inhibition of cancer cell proliferation, survival, and invasion through partial antagonism of c-MET phosphorylation [150,151].